Resources
177 Results (showing 51 - 60)
Results sorted by updated date (newest first)
Results sorted by updated date (newest first)
Posted 10/14/2021 (updated 4/3/2024)
Stimulant intoxication, withdrawal, and psychosis have accepted and established treatment strategies. Several lifesaving harm reduction interventions/services are available. There are no Food and Drug Administration-approved medications for treatment of stimulant use disorder, although several are promising. Behavioral treatment, especially the use of contingency management (and other approaches with supportive evidence), has by far the best evidence of effectiveness. The presenter reviewed topics of importance to clinicians treating individuals with stimulant use disorder.
Rick Rawson, PhD, University of Vermont Rural Center of Excellence
Posted 10/14/2021 (updated 4/3/2024)
Speakers from the University of Cincinnati and Ohio University/Pacific Institute for Research and Evaluation (PIRE) RCORP-Implementation cohort discussed their efforts in addressing stigma in their respective service areas.
Posted 10/14/2021 (updated 4/3/2024)
Presenters reviewed resources available to rural grantees through their respective agencies.
Posted 10/5/2021 (updated 4/3/2024)
This webinar focused on the crucial role of the emergency department (ED) in recognizing and treating opioid use disorder (OUD) patients with evidence-based medications for addiction treatment. Gail D’Onofrio, MD, discussed her pioneering work in creating the evidence for initiating ED buprenorphine treatment with ED patients presenting with opioid use disorder. Overall, the opioid epidemic intertwined with the COVID-19 pandemic has greatly escalated the need to mitigate the morbidity and mortality associated with the rising rate of fentanyl use. Data supporting the use of buprenorphine in the ED setting as well as the consequences of not initiating treatment will be discussed. While the use of ED prescribed buprenorphine has increased, universal adoption has lagged. Barriers to implementation of ED buprenorphine were discussed as well as strategies to overcome these challenges. Components of successful integration of an ED program with community partnerships was outlined. Current research by emergency physicians regarding innovative strategies such as high-dose buprenorphine inductions and use of extended release 7-day formulation of buprenorphine will be discussed. Initiation buprenorphine effectively, reduces withdrawal symptoms, improves adherence to treatment, and saves lives.
Posted 9/22/2021 (updated 4/3/2024)
PCSS's PCSS-Implementation (PCSS-I) initiative is here to support clinicians and their clinical programs by implementing medications for opioid use disorder (MOUD) into your practice.
PCSS-I has clinical and implementation experts as PCSS-I Facilitators available to work with you and your team to develop strategies tailored specifically to support your needs. There is no cost to participate.
Posted 12/15/2020 (updated 4/3/2024)
Dr. Seale led a discussion on communicating OUD needs in your community, building MOUD practice capacity, and other considerations and lessons learned from his work with individuals in rural communities.
Posted 12/15/2020 (updated 4/3/2024)
The presenters reviewed the structure and function of state substance use prevention systems, described the role and activities of the national prevention network, and highlighted rural prevention initiatives.
Posted 12/15/2020 (updated 4/3/2024)
Region 4 RCORP grantees share their experiences.
Posted 12/9/2020 (updated 4/3/2024)
Emergency Department initiated buprenorphine. This guide includes an overview, list of protocols, tools, and assessments for providers.
Posted 11/24/2020 (updated 4/3/2024)
Join your HRSA project officers and JBS TELS as they cover: A review of selected focus areas and prevention, treatment and recovery Strategies chosen by grantees, Using the Collective Impact Approach to develop your consortium, Creating an effective Logic Model and Developing an effective Strategic Plan.